Follow-Up Assessment Questions for Depression
When evaluating a patient with depression at follow-up, systematically assess four core domains using validated measurement tools: depressive symptom severity, medication adherence, side effects, and suicide risk. 1
Structured Assessment Approach
Primary Assessment Tools
The most practical and validated instruments for ongoing depression assessment in clinical practice are:
- PHQ-9 (9-item Patient Health Questionnaire): Tracks the nine DSM criteria for depression with scores indicating severity 1
- QIDS-SR or QIDS-C (16-item Quick Inventory of Depressive Symptomatology): Available in self-report or clinician-rated versions for comprehensive symptom monitoring 1
- FIBSER (Frequency, Intensity, and Burden of Side Effects Rating): Specifically evaluates medication tolerability 1
These tools should be administered at every follow-up visit to enable measurement-based care, which improves treatment outcomes and helps achieve sustained remission rather than just symptom response 1.
Critical Questions to Ask at Each Visit
Symptom Monitoring:
- Changes in the nine core depressive symptoms (mood, anhedonia, sleep, appetite, energy, concentration, psychomotor changes, guilt/worthlessness, suicidal thoughts)
- Specific attention to worthlessness, death wishes, and self-harm thoughts as these are strong predictors of current depressed mood 2
- Assessment of positive emotionality and impetus (drive/motivation) as separate subsyndromes that may respond differently to treatment 3
Treatment Response Assessment:
- Medication adherence patterns and barriers
- Timing and severity of side effects (particularly early gastrointestinal symptoms that commonly lead to treatment discontinuation) 4
- Functional improvement in work, relationships, and daily activities
- Progress toward complete remission, not just partial response 4
Safety Assessment:
- Direct questioning about suicidal ideation, intent, and plan at every visit
- Most patients appreciate being asked about mood in depth, including questions about death and self-harm 2
Implementation Strategy
Measurement-based care tactics should be combined with treatment algorithms so that assessment results directly inform clinical decisions at each visit 1. This systematic approach:
- Establishes baseline severity before treatment initiation
- Distinguishes medication side effects from residual depressive symptoms
- Guides decisions about dose adjustments, augmentation, or switching strategies
- Documents progress toward sustained remission
Common Pitfalls to Avoid
- Accepting partial response as adequate: The treatment goal must be complete remission, not just improvement 4
- Inadequate treatment duration: Continue treatment 6-9 months for first episodes, potentially lifelong for severe recurrent depression 4
- Failing to distinguish side effects from symptoms: Precise pre-treatment symptom evaluation helps differentiate these during follow-up 4
- Neglecting physical symptoms: Depression in primary care often presents with somatic complaints, particularly in patients with comorbid medical conditions 4
Evidence Quality Considerations
The recommendation for measurement-based care using PHQ-9, QIDS, and FIBSER comes from systematic analysis of depression treatment strategies 1. While the USPSTF guideline 5 demonstrates that screening alone without staff-assisted care support shows limited benefit, the key distinction is that follow-up assessment differs fundamentally from initial screening—you're monitoring treatment response in diagnosed patients, where these tools have proven utility in achieving better outcomes.
The assessment process itself is therapeutic: 92% of patients view comprehensive mood assessment positively and find it acceptable as a repeated measure 2. This validates the practice of systematic, detailed questioning at each follow-up visit.